Related Experiment Video
Updated: May 22, 2026
04:59
Rotating the Intraocular Lens to Prevent Posterior Capsular Opacification in Cataract Surgeries
Published on: July 7, 2023
Transient myopic shift after phakic intraocular lens implantation
Jose L Güell1, Merce Morral, Oscar Gris
1Cornea and Refractive Surgery Unit, Ophthalmology Department, Instituto de Microcirugia Ocular, Universitat Autonoma de Barcelona, Barcelona, Spain. guell@imo.es
Journal of Cataract and Refractive Surgery
|May 22, 2012
Summary
Spontaneous myopic shift can occur after Artiflex phakic intraocular lens (pIOL) implantation. Treatment with cyclopentolate drops or surgical reenclavation can restore vision.
Area of Science:
- Ophthalmology
- Optics
- Biomedical Engineering
Background:
- This study investigates a rare complication following Artiflex phakic intraocular lens (pIOL) implantation.
- The Artiflex pIOL is designed for refractive error correction.
Observation:
- Three patients developed spontaneous myopic shift 6 weeks to 6 months post-pIOL surgery.
- Corrected distance visual acuity (CDVA) remained stable in all affected patients.
- Optical coherence tomography revealed posterior pIOL displacement in one case.
Findings:
- Cyclopentolate drops effectively reversed the myopic shift in all patients.
- Two patients required surgical reenclavation of the pIOL for sustained refractive stability.
- All patients achieved 20/20 uncorrected distance visual acuity post-intervention.
- A minor reduction in objective optical quality was noted.
Implications:
- Spontaneous myopic shift is a potential complication of iris-claw pIOLs, possibly due to mechanical factors affecting iris and ciliary body dynamics.
- Prompt intervention with pharmacologic or surgical methods can successfully manage this complication.
- Understanding the mechanism is crucial for preventing and treating refractive instability after pIOL implantation.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:16Focusing of Light in the Eye
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...